Abstract
Prostate cancer is a molecularly heterogeneous disease, and mechanisms of action of
taxanes and potential mechanisms of resistance are not clearly defined. Taxanes are
microtubule-stabilizing agents resulting in the slowing or blocking of mitosis at
the metaphase–anaphase transition and induction of apoptotic cell death. Taxanes also
can inhibit androgen receptor pathway. To date, several factors have been associated
with taxane resistance, including alterations in tubulin, the effect of drug efflux
pumps, and the dysfunctional regulation of signaling pathways that may be involved
in resistance to therapy. Preclinical and clinical data support the distinct activity
of cabazitaxel in prostate cancer that may overcome resistance to prior taxanes or
hormonal therapies. It is challenging to define the most adequate therapeutic sequence
for each patient. Moreover, the identification of molecular markers of resistance
may help to select patients for specific therapies.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Genitourinary CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Mechanisms of action of taxanes in prostate cancer.Semin Oncol. 1999; 26: 3-7
- Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.N Engl J Med. 2004; 351: 1513-1520
- Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.N Engl J Med. 2004; 351: 1502-1512
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.Lancet. 2010; 376: 1147-1154
- Androgen receptor signaling in prostate cancer development and progression.J Carcinog. 2011; 10: 20
- Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial.Ann Oncol. 2013; 24: 2402-2408
- Enzalutamide in metastatic prostate cancer before chemotherapy.N Engl J Med. 2014; 371: 424-433
- Abiraterone and increased survival in metastatic prostate cancer.N Engl J Med. 2011; 364: 1995-2005
- Abiraterone in metastatic prostate cancer without previous chemotherapy.N Engl J Med. 2013; 368: 138-148
- Increased survival with enzalutamide in prostate cancer after chemotherapy.N Engl J Med. 2012; 367: 1187-1197
- Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?.Ann Oncol. 2012; 23: 2943-2947
- Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies.Eur Urol. 2015; 68: 228-235
- Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment: results of an Italian multicentre study.Eur Urol. 2015; 68: 147-153
- Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.Eur Urol. 2014; 66: 459-465
- Activity of cabazitaxel after docetaxel and abiraterone acetate therapy in patients with castration-resistant prostate cancer.Clin Genitourin Cancer. 2014; 12: 428-432
- CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.Int J Cancer. 2015; 136: E760-E772
- The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer.Eur J Cancer. 2015; 51: 2562-2569
- How do microtubule-targeted drugs work? An overview.Curr Cancer Drug Targets. 2007; 7: 730-742
- Targeting microtubules by natural agents for cancer therapy.Mol Cancer Ther. 2014; 13: 275-284
- Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.Oncology (Williston Park). 2014; 28: 693-699
- Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer.Cancer Res. 2011; 71: 6019-6029
- Androgen receptor on the move: boarding the microtubule expressway to the nucleus.Cancer Res. 2012; 72: 4611-4615
- Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer.Cancer Res. 2010; 70: 7992-8002
- Modulation of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer.Int J Biol Sci. 2014; 10: 614-619
- Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer.Cancer Res. 2009; 69: 8386-8394
- Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.Cancer Res. 2012; 72: 3457-3462
- Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.Proc Natl Acad Sci U S A. 2010; 107: 16759-16765
- AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.N Engl J Med. 2014; 371: 1028-1038
- Androgen receptor splice variants determine taxane sensitivity in prostate cancer.Cancer Res. 2014; 74: 2270-2282
- The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way.Prostate. 2013; 73: 267-277
- A transcription-independent function of FOXO1 in inhibition of androgen-independent activation of the androgen receptor in prostate cancer cells.Cancer Res. 2008; 68: 10290-10299
- Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents.Oncotarget. 2015; 6: 23358-23371
- AR splice variant 7 (AR-V7) and response to taxanes in men with metastatic castration-resistant prostate cancer (mCRPC).J Clin Oncol. 2015; 33 (Abstract 138)
- Efficacy of cabazitaxel in castration-resistant prostate cancer is independent of the presence of AR-V7 in circulating tumor cells.Eur Urol. 2015; 68: 939-945
- BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability.J Biol Chem. 2005; 280: 12902-12907
- Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy.Cancer Res. 2010; 70: 9253-9264
- Expression of multidrug resistance related proteins and proliferative activity is increased in advanced clinical prostate cancer.J Urol. 2001; 165: 130-135
- Inhibition of PI3Kbeta signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.Mol Cancer Ther. 2015; 14: 48-58
- Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.Clin Cancer Res. 2006; 12: 5578-5586
- Nuclear factor-kappa B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer.Prostate. 2013; 73: 512-521
- Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells.Cancer Cell. 2012; 22: 373-388
- Identification of docetaxel resistance genes in castration-resistant prostate cancer.Mol Cancer Ther. 2012; 11: 329-339
- ERG induces taxane resistance in castration-resistant prostate cancer.Nat Commun. 2014; 5: 5548
Reig O, Marin-Aguilera M, Carrera G, et al. TMPRSS2-ERG in blood and docetaxel response in metastatic castration-resistant prostate cancer. European Cancer Congress (ECC) 2015. Available at: https://www.europeancancercongress.org/Vienna2015/Scientific-Programme/Searchable-Programme?trackid=00222#anchorScpr. Accessed: January 15 2016.
- Improving cabazitaxel chemical stability in parenteral lipid emulsions using cholesterol.Eur J Pharm Sci. 2014; 52: 1-11
- Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors.Clin Cancer Res. 2013; 19: 2973-2983
- Preclinical profile of cabazitaxel.Drug Des Devel Ther. 2014; 8: 1851-1867
- Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer.Eur Urol. 2014; 65: 1198-1204
- Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours.BMC Cancer. 2013; 13: 460
- Can taxanes provide benefit in patients with CNS tumors and in pediatric patients with tumors? An update on the preclinical development of cabazitaxel.Cancer Chemother Pharmacol. 2013; 72: 515-528
- Efficacy of cabazitaxel in mouse models of pediatric brain tumors.Neuro Oncol. 2015; 17: 107-115
- Cabazitaxel in castration resistant prostate cancer with brain metastases: 3 case reports.World J Clin Cases. 2014; 2: 228-231
- Antiproliferative mechanism of action of the novel taxane cabazitaxel as compared with the parent compound docetaxel in MCF7 breast cancer cells.Mol Cancer Ther. 2014; 13: 2092-2103
- Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer.Nat Rev Cancer. 2015; 15: 701-711
- N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy.Mol Oncol. 2014; (Nov 15. pii: S1574-7891(14)00263-4. http://dx.doi.org/10.1016/j.molonc.2014.10.014)
- Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.Eur J Cancer. 2013; 49: 3821-3830
- Targeting the androgen receptor confers in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in castration-resistant prostate cancer.Eur Urol. 2015; 67: 981-985
- Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.Clin Cancer Res. 2015; 21: 795-807
- Chemohormonal therapy in metastatic hormone-sensitive prostate cancer.N Engl J Med. 2015; 373: 737-746
- Docetaxel and/or zoledronic acid for hormonenaïve prostate cancer: first overall survival results from STAMPEDE (NCT00268476).J Clin Oncol. 2015; 33 (Abstract 5001)
Article info
Publication history
Published online: December 27, 2015
Accepted:
December 19,
2015
Received in revised form:
December 18,
2015
Received:
October 8,
2015
Identification
Copyright
© 2015 Elsevier Inc. All rights reserved.
